

091674913

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO. PCT/NO99/00141	INTERNATIONAL FILING DATE April 30, 1999	PRIORITY DATE CLAIMED May 8, 1998
---	---	--------------------------------------

TITLE OF INVENTION

Frameshift Mutants of Beta-Amyloid Precursor Protein and Ubiquitin-B and Their Use

APPLICANT(S) FOR DO/EO/US

Gustav GAUDERNACK, Jon Amund ERIKSEN and Mona MØLLER ✓

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)).
4. The US has been elected by the expiration of 19 months from the priority date (PCT Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. is attached hereto (required only if not communicated by the International Bureau).
 - b. has been communicated by the International Bureau.
 - c. is not required, as the application was filed in the United States Receiving Office (RO/US).
6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. are attached hereto (required only if not communicated by the International Bureau).
 - b. have been communicated by the International Bureau.
 - c. have not been made; however, the time limit for making such amendments has NOT expired.
 - d. have not been made and will not be made.
8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 16 below concern other document(s) or information included:

11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. A **FIRST** preliminary amendment.
 - A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. A substitute specification.
15. A change of power of attorney and/or address letter.
16. Other items or information:
 - (i) Sequence Listing - Paper Copy
 - (ii) Sequence Listing - Computer Readable Copy (i.e., diskette)
 - (iii) Statement Under 37 C.F.R. § 1.821(f)
 - (iv) International Search Report
 - (v) International Preliminary Examination Report

17. The following fees are submitted:**Basic National Fee (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1000.00

International preliminary examination fee (37 CFR 1.482 not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00

International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 1000 00

Surcharge of **\$130.00** for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

Claims	Number Filed	Number Extra	Rate	
<input type="checkbox"/> Total Claims	66-20 =	46	X \$18.00	\$ 828 00
<input checked="" type="checkbox"/> Independent Claims	1- 3 =	0	X \$80.00	\$ 0 00
Multiple dependent claim(s) (if applicable)			+ \$270.00	\$ 270 00

TOTAL OF ABOVE CALCULATIONS =

\$ 00

Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by $\frac{1}{2}$.

\$ 00

SUBTOTAL = \$ 2098 00

Processing fee of **\$130.00** for furnishing the English translation later than 20 30 months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

TOTAL NATIONAL FEE = \$ 2098 00

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00** per property +

\$

TOTAL FEES ENCLOSED = \$ 2098 00**Amount to be:****refunded** \$**charged** \$

- A check in the amount of \$2098.00 to cover the above fees is enclosed.
- Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 06-1205. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

FITZPATRICK, CELLA HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200



SIGNATURE

John W. Behringer

NAME

23,086

REGISTRATION NUMBER

November 8, 2000

DATE

09/674913
529 Rec'd PCT/PTC 08 NOV 2000

1702.401600

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
GUSTAV GAUDERNACK, ET AL.) : Examiner: Unassigned
Int'l Appln. No.: PCT/N099/00141) : Group Art Unit: Unassigned
Int'l Publn. No.: WO 99/58564) :
U.S. Appln. No.: Unassigned) :
Nat'l Entry Date: November 8, 2000) :
For: FRAMESHIFT MUTANTS OF) November 8, 2000
BETA-AMYLOID PRECURSOR :
PROTEIN AND UBIQUITIN-B)
AND THEIR USE :
TREC2500-E1500-2960

Commissioner For Patents
Washington, D.C. 20231


STATEMENT UNDER 37 C.F.R. § 1.821(f)

Sir:

Applicants hereby submit that the sequence listing information recorded in computer readable form on the attached diskette is identical to the written sequence listing filed concurrently herewith.

Applicants' undersigned attorney may be reached in our Washington, D.C. office by telephone at (202) 530-1010. All correspondence should be directed to our address listed below.

Respectfully submitted,


John W. Behringer
Reg. No. 23,086
Attorney for Applicants

FITZPATRICK, CELLA, HARPER & SCINTO
30 Rockefeller Plaza
New York, New York, 10112-3801
Facsimile: (212) 218-2200

NMD\vjw

Assistant Commissioner for Patents
Washington, D.C. 20231

Date 11/8/00
Mo. Day Yr.
Atty. Docket 1702-401600

Sir:

Kindly acknowledge receipt of the accompanying: and PCT cover page

- Specifications, claims and abstract 24 pages, with Transmittal Form 37 CFR 1.8 Under 37 CFR 1.371
 Oath or Declaration and Power of Attorney Executed Not Executed
 _____ Sheets of _____ formal _____ informal drawings
 Check for \$ 2098.00 (filing fee)
 Small entity declaration
 Assignment, PTO-1595 and Check for \$ _____
 Transmittal Under 37 CFR 1.53(d) (CPA)
 Petition under 37 CFR 1.136 and check for \$ _____
 Other (specify) Like here copy of Sequence listing; Statement Under 37 CFR 1.831(e); Preliminary Amendment; Entitle Search Report by placing your receiving date stamp hereon and mailing or returning to deliverer
This is a Continuation Divisional Continuation-In-Part Art. 14 Ck in Amendments

Atty. J.W. Johnson Jr.

Due Date 11/8/00
Mo. Day Yr.

37 CFR 1.8
 37 CFR 1.10
 By Hand



98-1702